



DEFENSE INTELLIGENCE AGENCY

DIA_C_01570_A

April 21, 2020

(U) Worldwide: Progress of COVID-19 Vaccine Development

(b)(3):10 USC 424; (b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

[Redacted content]

Committed to Excellence in Defense of the Nation

(U) Status of COVID-19 Vaccine Development

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

(b)(1); (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

(U) This graphic represents the most-advanced COVID-19 vaccine development as of 17 April 2020. The two most promising vaccine approaches are an mRNA-based vaccine, which instructs the patient's immune system to produce proteins that could prevent disease, and an adenovirus-based vaccine, which inserts a relevant COVID-19 gene into another innocuous virus to produce a robust antibody response.³⁴

(b)(3):10 USC 424; (b)(3):50 USC 3024(i)

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

The following page is withheld in full citing (b)(1), (b)(3) 10 USC 424 + 50 USC 3024(i), and is not provided.

(b)(1); (b)(3):10 USC 424; (b)(3):50 USC 3024(i); Sec. 1.4(c); Sec. 1.4(e)

³⁴ (U) Book, Shakti Singh et al | 11 Nov 2018 | 11 Nov 2018 | (U) Adenoviral Vector-Based Vaccines and Gene Therapies: Current Status and Future Prospects | <https://www.reseachgate.net/publication/328875899>, 01 Apr 2020

(b)(3):10 USC 424